Immune checkpoint inhibitors, such as Merck & Co.’s Keytruda and GlaxoSmithKline’s Jemperli, and targeted therapies, such as Eisai’s Lenvima, have revolutionized the therapeutic landscape of…
The ovarian cancer market in China is poised to experience substantial market growth over the 2021-2031 forecast period. For patients with ovarian cancer, chemotherapy regimens remain the go-to…
Clarivate Epidemiology’s coverage of glioma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the incidence of glioma for each country, as well…
Since 2015, eight new brands have launched into the highly generic U.S. Parkinson’s disease (PD) therapy market, and six more are expected to launch soon. Chronic polypharmacy and progressive…
Clarivate Epidemiology’s coverage of NK/T-cell lymphoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s coverage of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) comprises epidemiological estimates of key patient populations in 45 countries worldwide…